Alpine Immune Sciences Inc
ALPN
Market Cap$4.22B
Close$
$37.58
41.6% downside
Current Fair Value
41.6% downsideOvervalued by 41.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.22 Billion |
|---|---|
| Enterprise Value | $3.90 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.64 |
| Beta | 1.81 |
| Outstanding Shares | 65,546,136 |
| Avg 30 Day Volume | 3,848,020 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -131.16 |
|---|---|
| PEG | 99.67 |
| Price to Sales | - |
| Price to Book Ratio | 12.87 |
| Enterprise Value to Revenue | 66.3 |
| Enterprise Value to EBIT | -88.22 |
| Enterprise Value to Net Income | -122 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
ESG Score
No data
About Alpine Immune Sciences Inc
CEO: Mitchell Gold